IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

We are a medical device company focused on the development of interventional pulmonology products. Founded in 2012, we are a pioneer in the field of interventional pulmonology, providing innovative lung solutions in China and globally. Leveraging our whole lung access navigation technology and encompassing navigation, diagnosis and treatment, our integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and significant unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. As of the Latest Practicable Date, we had 17 products and major product candidates under various development stages as set forth in the pipeline chart below. Our Core Products are the InterVapor system (the “InterVapor”) and RF Generator + RF Ablation Catheter (“RF-II”). InterVapor is the world’s first and only thermal vapor energy ablation system to treat lung diseases including COPD and lung cancer, according to Frost & Sullivan. RF-II is a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter and the only radiofrequency ablation system that specifically targets lung cancer. As of the Latest Practicable Date, we had 132 and 60 patents and patent applications related to InterVapor and RF-II, respectively. There is no assurance that we will ultimately be able to develop and market our Core Products successfully. Led by our experienced management team with an average of over 20 years of experience in designing, developing and commercializing medical devices, we believe that by leveraging on their expertise, we are well positioned to capture the commercial opportunities in the large and fast-growing market for the lung disease treatment with a focus on chronic obstructive pulmonary disease (“COPD”) and lung cancer in China and globally. We also benefit from our stable and dedicated senior management personnel with complimentary background and expertise. Members of our board and management team have experience in commercializing medical devices such as peripheral vascular intervention products, and our transcatheter aortic valve replacement systems in China, the U.S. and Europe. We are backed by a number of large institutional investors focused on the healthcare sector, such as Qiming Venture Capital, DiNovA Capital, LAKE Bleu Capital and FountainVest, and strategic investors including Intuitive Surgical, a global technology leader in robotic-assisted, minimally invasive surgical platforms and diagnostic tools listed on the Nasdaq Stock Market (NASDAQ: ISRG). Source: Broncus-B (02216) Prospectus (IPO Date : 2021/09/13)
Listing Market	MAIN
Industry	Biotechnology
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Zhenjun Zi & Associates (17.10%) Qiming Corporate GP IV, Ltd. (16.61%) Computershare Hong Kong Trustees Limited (7.49%)
Directors	Hong XU (Chairman and Chief Executive Officer and Chief Technology Officer and Executive Director) Ao ZHANG (Non-Executive Director) Yanhong Kuang (Non-Executive Director) Pok Man KAM (Independent Non-Executive Director) Wong Yee Sin (Independent Non-Executive Director) David Scott Lim (Independent Non-Executive Director)
Company Secretary	Suen Ka Yan
Principal Bankers	CITIC Bank, China
Solicitors	Davis Polk & Wardwell
Auditors	Ernst & Young
Registered Office	40th Floor, Dah Sing Financial Centre, No. 248 Queen’s Road East Wanchai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.broncus.com
Email Address	ir@broncuschina.com
Tel No
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates